<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04496284</url>
  </required_header>
  <id_info>
    <org_study_id>RMA-2020-03</org_study_id>
    <nct_id>NCT04496284</nct_id>
  </id_info>
  <brief_title>Embryo Transfer Outcomes After Vitrification With Slush Nitrogen Compared to Liquid Nitrogen</brief_title>
  <official_title>Embryo Transfer Outcomes After Vitrification With Slush Nitrogen Compared to Liquid Nitrogen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reproductive Medicine Associates of New Jersey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Reproductive Medicine Associates of New Jersey</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed study is a single-blind randomized controlled trial which seeks to characterize&#xD;
      implantation rates following embryo vitrification and subsequent warming with both slush&#xD;
      nitrogen and liquid nitrogen. After warming, implantation rates and pregnancy outcomes will&#xD;
      be assessed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine if slush nitrogen for embryo vitrification results&#xD;
      in higher sustained implantation rates compared to the conventional use of liquid nitrogen.&#xD;
      Routine ovarian stimulation, oocyte retrieval and embryology care will ensue. All blastocyst&#xD;
      stage embryos will be randomized to either the control (liquid nitrogen) or intervention&#xD;
      group (slush nitrogen) and vitrified after trophectoderm biopsy has been performed for PGT-A&#xD;
      (preimplantation genetic testing for aneuploidy). A single, chromosomally normal embryo will&#xD;
      be transferred in a subsequent frozen embryo transfer cycle per routine. Implantation rates&#xD;
      and pregnancy outcomes will be assessed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 5, 2020</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>sustained implantation rate</measure>
    <time_frame>approximately 8 weeks gestation age</time_frame>
    <description>fetal heart beat present upon discharge at 8 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical pregnancy rate</measure>
    <time_frame>usually by 5 weeks gestational age</time_frame>
    <description>presence of gestational sac in uterus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>miscarriage rate</measure>
    <time_frame>1-8 months dependent on gestational age of loss</time_frame>
    <description>pregnancy loss</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>live birth rate</measure>
    <time_frame>9 months</time_frame>
    <description>delivery of live infant</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Vitrification via slush nitrogen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blastocyst stage embryos will be vitrified via slush nitrogen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitrification via liquid nitrogen</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Blastocyst stage embryos will be vitrified via conventional liquid nitrogen. This is the current standard of care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vitrification via slush nitrogen</intervention_name>
    <description>blastocyst stage embryos will be vitrified via slush nitrogen</description>
    <arm_group_label>Vitrification via slush nitrogen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Major Inclusion Criteria for participants:&#xD;
&#xD;
          1. Patients undergoing IVF stimulation cycle with plan for subsequent frozen embryo&#xD;
             transfer (FET)&#xD;
&#xD;
          2. Patients electing preimplantation genetic testing for aneuploidy (PGT-A)&#xD;
&#xD;
          3. Couples electing single embryo transfer (SET)&#xD;
&#xD;
        Major Exclusion Criteria for participants:&#xD;
&#xD;
          1. All patients who do not voluntarily give their written consent for participation&#xD;
&#xD;
          2. Under 18 years old, above 42 years old&#xD;
&#xD;
          3. BMI &gt; 35&#xD;
&#xD;
          4. Maximum day 3 Follicle stimulating hormone (FSH) level of 12 or higher&#xD;
&#xD;
          5. Anti-mullerian hormone (AMH) level less than 1.0 g/mL, tested within previous year&#xD;
&#xD;
          6. Total basal antral follicle count less than 6 follicles&#xD;
&#xD;
          7. Failed more than one previous FET cycle&#xD;
&#xD;
          8. Use of oocyte donation&#xD;
&#xD;
          9. Use of gestational carrier&#xD;
&#xD;
         10. Presence of hydrosalpinges that communicate with endometrial cavity&#xD;
&#xD;
         11. Diagnosis of endometrial insufficiency: prior cycle with maximal endometrial thickness&#xD;
             â‰¤ 6mm, abnormal endometrial pattern (failure to attain a trilaminar appearance),&#xD;
             persistent endometrial fluid&#xD;
&#xD;
         12. Uncorrected uterine factor infertility (uterine anomaly, submucosal myomas, uterine&#xD;
             septum)&#xD;
&#xD;
         13. Single gene disorder chromosomal rearrangement requiring a more detailed embryonic&#xD;
             genetic analysis&#xD;
&#xD;
         14. Male partner with &lt;100,000 total motile spermatozoa per ejaculate (donor sperm is&#xD;
             acceptable)&#xD;
&#xD;
         15. Use of surgical procedures to obtain sperm&#xD;
&#xD;
         16. Couples undergoing IVF for fertility preservation with no immediate plan for&#xD;
             subsequent FET (embryo banking)&#xD;
&#xD;
         17. Sex selection&#xD;
&#xD;
         18. Personal history of repeated pregnancy loss (two or more unexplained clinical losses&#xD;
             defined by presence of fetal heartbeat)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christine V Whitehead, BSN,RN</last_name>
    <phone>973-656-2841</phone>
    <email>clinicalresearchteam@ivirma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Caroline Zuckerman, BS</last_name>
    <phone>973-656-2841</phone>
    <email>clinicalresearchteam@ivirma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Reproductive Medicine Assoicates of New Jersey</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine V Whitehead, BSN, RN</last_name>
      <phone>973-656-2841</phone>
      <email>clinicalresearchteam@ivirma.com</email>
    </contact>
    <contact_backup>
      <last_name>Caroline Zuckerman, BS</last_name>
      <phone>973-656-2841</phone>
      <email>clinicalresearchteam@ivirma.com</email>
    </contact_backup>
    <investigator>
      <last_name>Richard T Scott, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>July 28, 2020</study_first_submitted>
  <study_first_submitted_qc>July 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2020</study_first_posted>
  <last_update_submitted>September 14, 2020</last_update_submitted>
  <last_update_submitted_qc>September 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

